|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
This article reviews PTP1B as a novel target for type 2 diabetes, and looks at the challenges in developing small-molecule inhibitors of this phosphatase.
|
12209150 |
2002 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings displayed the potential of WSZYF as a new drug candidate in the treatment of T2DM and the antidiabetic mechanism of WSZYF is probably mediated through modulating the PTP1B-IRS1-Akt-GLUT4 signaling pathway.
|
29479370 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a validated therapeutic target for Type 2 diabetes due to its specific role as a negative regulator of insulin signaling pathways.
|
29912965 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The review describes the effectiveness of potent PTP1B inhibitors as pharmaceutical agents to treat type 2 diabetes.
|
31402706 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, the protein tyrosine phosphatase PTP-1B has been shown to be a negative regulator of the insulin signaling pathway, suggesting that inhibitors of this enzyme may be beneficial in the treatment of type 2 diabetes.
|
10665340 |
1999 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
As part of our ongoing research project for discovering bioactive substances from Chinese marine invertebrates, compounds 1 - 8 were tested for their inhibitory activity against protein tyrosine phosphatase 1B (PTP1B), a key target for the treatment of Type-II diabetes and obesity.
|
28323380 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hit, Lead & Candidate Discovery Protein tyrosine phosphatase 1B (PTP-1B) has attracted interest as a novel target for the treatment of type 2 diabetes, this because its role in the insulin-signaling pathway as a negative regulator.
|
29380400 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) has been proposed to be an ideal target for treatment of type II diabetes and obesity.
|
28111140 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein Tyrosine Phosphatase 1B (PTP1B), an important negative regulator of insulin signaling, is thought to be an attractive therapeutic target for insulin resistance and type 2 diabetes.
|
17286230 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a promising target for type II diabetes, obesity, and cancer therapeutics, plays an important negative role in insulin signaling pathways.
|
29608303 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is an important target for type 2 diabetes.
|
31743023 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, some of the tested flavonoids seem to be promising PTP1B inhibitors and potential effective agents in the management of T2DM, by increasing insulin sensitivity.
|
29175190 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is an attractive target for treating cancer, obesity, and type 2 diabetes.
|
29441120 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
To search for association between the PPARgamma, calpain 10, PTPN1 genes and DR in type 2 diabetes mellitus (T2DM).
|
18077048 |
2008 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, dual antagonists by targeting both α-glucosidase and PTP1B may be potential candidates for type 2 diabetes therapy.
|
29745030 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This article reviews PTP 1B inhibitors; natural, synthetic and semi-synthetic that showed inhibition towards enzyme as a major target for the management of type II diabetes.
|
28043717 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatase PTP1B has become a therapeutic target for the treatment of type 2-diabetes, whereas recent studies have revealed that PTP1B plays a pivotal role in pathophysiology and development of breast cancer.
|
31419504 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The development of small molecular inhibitors targeting PTP1B has been validated as a potential therapeutic strategy for Type 2 diabetes (T2D).
|
31221555 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) has been regarded asa target for the research and development of new drugs to treat type II diabetes and PTP1B inhibitors are potential lead compounds for this type of new drugs.
|
28946049 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a known regulator of the insulin and leptin signaling pathways and is an active target for the design of inhibitors for the treatment of type II diabetes and obesity.
|
27959494 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In summary, a rare P387L variant of the PTP-1B gene is associated with a 3.7 (CI 1.26-10.93, P = 0.02) genotype relative risk of type 2 diabetes in the examined population of Danish Caucasian subjects and results in impaired in vitro serine phosphorylation of the PTP-1B peptide.
|
11756316 |
2002 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTPN1 is located in 20q13, a genomic region linked to type 2 diabetes in multiple genetic studies.
|
15504984 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
To this aim, the phenolic composition, the activity on protein tyrosine phosphatase 1B (PTP1B), an enzyme overexpressed in type-II diabetes, the in vitro prebiotic properties on <i>Lactobacillus</i><i>reuteri</i> and the microbial composition were investigated.
|
30901847 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
|
31309546 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Both new compounds (<b>8</b> and <b>9</b>) exhibited promising inhibitory activity against protein tyrosine phosphatase 1B (PTP1B), a potential drug target for the treatment of type II diabetes and obesity.
|
29587405 |
2018 |